
Gensight Biologics SA
PAR:SIGHT

Gensight Biologics SA
Net Change in Cash
Gensight Biologics SA
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Gensight Biologics SA
PAR:SIGHT
|
Net Change in Cash
€5.9m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Valneva SE
PAR:VLA
|
Net Change in Cash
-€14.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Innate Pharma SA
PAR:IPH
|
Net Change in Cash
-€1.4m
|
CAGR 3-Years
63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
G
|
Genfit SA
PAR:GNFT
|
Net Change in Cash
-€50.2m
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Inventiva SA
PAR:IVA
|
Net Change in Cash
-€21.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
![]() |
Eurobio Scientific SA
PAR:ALERS
|
Net Change in Cash
€15.8m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
68%
|
CAGR 10-Years
6%
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

See Also
What is Gensight Biologics SA's Net Change in Cash?
Net Change in Cash
5.9m
EUR
Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Net Change in Cash amounts to 5.9m EUR.
What is Gensight Biologics SA's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
-46%
The average annual Net Change in Cash growth rates for Gensight Biologics SA have been -46% over the past three years .